TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals, Inc. is a clinical stage pharmaceutical company committed to extending a healthy lifespan. Formerly known as MyMD Pharmaceuticals, Inc., TNF Pharmaceuticals is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms.

MYMD-1® is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation.

The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs.

Founded in 2014, TNF Pharmaceuticals is positioning itself in the pharmaceutical industry with a focus on innovative drug development. As of now, there is no public information available about the company's headquarters, last investment, or last investment investors.